Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB-502 + HB-501
- Development stage
- Unknown
- Lead developer
- HOOKIPA Pharma
- Modality
- Gene Therapies, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Intramuscular
01
Overview
HB-502 + HB-501 is an investigational combination therapy developed by Hookipa Biotech for the treatment of HIV infection. This therapy utilizes two alternating viral vector-based immunotherapies (HB-502 and HB-501) designed to train the immune system to recognize and mount a response against HIV antigens. The approach aims to stimulate robust anti-HIV immunity in people living with HIV who are already receiving antiretroviral therapy (ART). The combination is administered via intramuscular injection every 8 weeks over a 24-week period, followed by an additional observation period for safety and immunogenicity assessment. As of now, this combination is being evaluated in Phase 1 clinical trials[1][2][3].
- Other names
- HB-501/HB-502 alternating vector therapyHB-500 seriesHB500 seriesHB 500 series
02
Targets
Gag (HIV-1 Gag polyprotein)Nef (HIV-1 Nef)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on HB-502 + HB-501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB-502 + HB-501.